• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options on May 11, 2026 to acquire 9,500 common shares at USD 146.03.
• Rothblatt sold 9,500 common shares same day in multiple trades at weighted-average prices ranging from USD 569.5 to USD 580.44.
• Directly held common shares fell to 40,513 following transactions.
• Directly held stock options declined to 15,288 following exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000051), on May 12, 2026, and is solely responsible for the information contained therein.